Your weekly recap of news and analysis from the psychedelic sector.
Psychedelic Bulletin: Psychedelics Index Published; ETF Launching Jan 27; MindMed Commences Candyflipping Trial
This Week: North American Psychedelics Index is published, MindMed commences candyflipping trial, Cybin and Mind Cure announce $20m bought deal offerings, and more…
Psychedelic Bulletin: Psychedelics Companies Embrace Tech; MindMed to Study LSD Microdosing; UFC Eyes Psychedelics
This Week: Psychedelics companies increasingly embrace adjunct technologies; MindMed announces LSD Microdosing study; UFC reaches out to Johns Hopkins regarding psychedelics…
Psychedelic Bulletin: MindMed Raises $92.1m; Mount Sinai Establishes Psychedelics Centre; More Legal Exemptions for Psilocybin in Canada
This Week: MindMed closed a $92.1m raise, COMPASS Pathways and Mount Sinai established centres dedicated to psychedelic therapy and research, more Canadians receive legal exemptions for psilocybin-assisted therapy…
Psychedelic Bulletin: First Psychedelic ETF Set to Launch; Beckley Psytech Raises £14m; Reviewing the Psychedelic Renaissance in 2020
This Week: Among coverage of a number of raises, and the first psychedelic ETF, we round off a remarkable year for psychedelics, and the world more broadly.
Psychedelic Bulletin: MindMed Raises $34.5m; Tryp Goes Public; What Health Canada’s Latest Amendment Means for Psychedelics
This Week: Canada to consider allowing psychedelic therapy under Special Access Program; MindMed raises $34.5m, announces $80m offering; Tryp goes public.
This week: 17 Canadian healthcare professionals receive approval to use psilocybin; UK regulators approve DMT for depression trial; capital continues to flow into the psychedelic space.